Who Owns Cognition Therapeutics Stock?
NASDAQ: CGTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 23.79%
- Held by insiders
- 1.29%
- Institutional holders
- 73
- Institutions 23.8%
- Insiders 1.3%
- Public and other 74.9%
Who owns Cognition Therapeutics stock?
Institutional investors own about 23.8% of Cognition Therapeutics's shares, spread across 73 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 1.29% of CGTX.
The largest institutional holders are Bios Capital Management, LP (6.31%), Davenport & Co LLC (4.48%) and Vanguard Capital Management LLC (3.62%). Together, the top 10 institutions control 20.1% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their CGTX positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CGTX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Bios Capital Management, LP | 6.00M | 6.31% | 0.0% |
| Davenport & Co LLC | 4.26M | 4.48% | +47.2% |
| Vanguard Capital Management LLC | 3.44M | 3.62% | +14.6% |
| Blackrock Inc. | 1.26M | 1.33% | +30.3% |
| Chescapmanager LLC | 997.03K | 1.05% | 0.0% |
| Geode Capital Management, LLC | 910.01K | 0.96% | -1.1% |
| Renaissance Technologies, LLC | 693.29K | 0.73% | -37.9% |
| Hilton Capital Management, LLC. | 548.95K | 0.58% | 0.0% |
| Vanguard Fiduciary Trust Co | 508.22K | 0.53% | +9.6% |
| CM Management, LLC | 450.00K | 0.47% | +12.5% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CGTX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.44M | 2.57% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 871.60K | 0.92% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 418.88K | 0.44% |
| iShares Trust-iShares Micro-Cap ETF | 273.42K | 0.29% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 143.66K | 0.15% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 118.70K | 0.12% |
| SCHWAB CAPITAL TRUST-Schwab Total Stock Market Index Fund | 84.94K | 0.09% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 51.05K | 0.05% |
| VANGUARD VALLEY FORGE FUNDS-Vanguard Balanced Index Fund | 38.78K | 0.04% |
| VANGUARD Inst. INDEX Fd.S-Vanguard Inst. Total Stock Market Index Fd. | 31.80K | 0.03% |
Frequently asked questions
Who is the largest shareholder of Cognition Therapeutics?
Bios Capital Management, LP is the largest institutional shareholder of CGTX, owning 6.31% of shares outstanding (6.00M shares) as of its latest 13F filing.
What percentage of Cognition Therapeutics is owned by institutions?
Institutions own about 23.8% of CGTX shares and 24.1% of the public float.
How much of Cognition Therapeutics do insiders own?
Insiders, such as officers and directors, own about 1.29% of CGTX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.